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1. IntroductIon
Growth factors may be defined as any group of protein 
that stimulate the growth of specific tissues and play an 
important role in promoting cellular differentiation and 
cellular division1. Growth factors generally act through 
paracrine and autocrine signaling. Contrary to original 
belief, they may also act in endocrine manner. Among these 
autocrine mechanism is thought to play a significant role in 
growth of cancer cells2,3. Growthfactors have diverse mode 
of action but mostly act through tyrosine kinase receptor 
pathway. Tyrosine kinase receptors are membrane bound 
complexes having intrinsic kinase activity on cytoplasmic 
domain. Upon binding of specific growth factors (ligand) 
their kinase activity is activated and they phosphorylate 
their downstream targets on their tyrosine and serine 
residues to recruit other molecules into signaling cascades3.
1.1 Growth Factors: role in Imparting an 
Important Hallmark of cancer
Cancer is defined as a cell that grows uncontrollably 
and hence sustaining chronic proliferation is the most 
important characteristic of cancer5. This excellent 
proliferative property is imparted largely by growth factors.
Literature suggests link between oncogenes and 
growth factors6:
1. ProtooncogeneC-sis codes for B-chain of PDGF7
2. C-erb codes for EGF receptor8
3. C-fms oncogene is similar to CSF-19.
Secondly, evidences suggest that growth factors can 
increase transcription of certain proto-oncogene (myc and 
fos)10. Cancer cells may produce growth factors themselves 
or may send signals to stimulate normal cells to secrete 
growth factors5.
2. classIFIcatIon oF GrowtH Factors
Growth factors are generally classified in following 
classes4:
2.1 Platelet derived Growth Factor Family
Platelet derived growth factor (PDGF) is initially 
released from alpha-granules of platelets and act as a 
chemoattractant for fibroblasts and as mitogenfor these 
s no. Growth factors1. Platelet derived growth factor family 2. Vascular endothelial growth factor family
3. Epidermal growth factor family4. Fibroblast growth factor family 5. Transforming growth factor-B family6. The Insulin family7. Hepatocyte growth factor family8. Neurotrophin family9. The Ephrin family10. Angiopoietins
Table 1. Growth factors are generally classified
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cells11. PDGF stimulates production of collagenase by 
fibroblasts causing remodeling of matrix required for tissue 
repair12. It is also released from activated macrophages13. 
Platelet derived growth factor (PDGF) family of growth 
factor consists of 5 different disulphide linked dimmers 
PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC and PDGF-DD 
that act via 2 receptors PDGFRα and PDGFRβ19. Platelet 
derived growth factor receptors (PDGFR) are receptors 
with intrinsic tyrosine kinase activity that regulates 
several functions in normal cells14. PDGFR play a role in 
development of lungs, heart, CNS and kidney15. Inaddition 
to physiological functions, PDGF play pathological roles in 
disease such as atherosclerosis16, glomerulonephritis17 and 
cancer18.
In context of cancer, PDGF help in blood vessel 
formation, cell migration and metastasis. Overexpression 
of V-sis oncogene product PDGF enhances transformation19. 
PDGF signaling is critical for cell-cell communication as 
PDGF ligands are expressed and secreted by epithelial or 
endothelial cells to recruit and activate PDGF receptors in 
stromal components such as smooth muscle cells, pericytes 
and fibroblasts. Cancer cells express PDGF ligands and 
its cognate receptors, hence inducing both autocrine and 
paracrine signaling which helps in cancer progression18.
Expression of PDGFRα has been reported in breast 
carcinoma. According to clinical studies on human breast 
cancer samples 39.2% of invasive ductal carcinoma PDGFRα 
is present which attributes aggressiveness as it metastasizes 
to lymph nodes and shows HER2 and Bcl2 expression19. 
Simultaneous expression of PDGF-A and PDGFR-α in 
epithelium, stroma and endothelium of invasive breast 
carcinoma suggests possibility of autocrine and parcrine 
signaling which promotes angiogenesis. Hence PDGFα has 
emerged as a potential target of breast cancer20. PDGFRβ 
is upregulated and activated in prostate cancer of which it 
is overexpressed in 88% of primary prostate cancer and 
80% of metastasized bone lesions21. PDGF-D was identified 
as a ligand for PDGFRβ and the serine protease matripase 
as its extracellular proteolytic activator in prostate 
cancer22. PDGF-BB isoform promotes growth of human 
oseophageal carcinoma cell lines and prevents apoptosis 
of cancer cells23. Additionally overexpression of PDGFRβ 
is associated with tissues of esophageal cancer24. PDGF-C 
and PDGF-D ligands play a role in development of brain 
tumor and PDGF autocrine signaling regulates survival and 
mitogenic pathway in glioblastoma18. In coordination with 
these studies it has also been found that antitumor effect 
of chemotherapeutic agents can be enhanced by inhibiting 
PDGF receptor signaling in tumor stroma.
2.2 Vascular Endothelial Growth Factor Family
Humam vascular endothelial growth factor (VEGF) 
family consists of VEGF-A,VEGF-B, VEGF-C, VEGF-D and 
Placental Growth factor25. There are 3 receptor which are 
regulated by protein kinase for VEGF family of ligands: 
VEGFR1, VEGFR2, VEGFR3. And two non-enzymatic 
receptors: Neuropilin1 and Neuropilin-226. VEGF is 
secreted by any cell that encounters hypoxia27. VEGF acts 
as a mitogen thereby being important survival factor for 
endothelial cells and monocyte motility28. VEGF changes 
permeability of endothelial cells by causing injury to help 
angiogenesis29.
Major factors regulating VEGF includes growth factors, 
local environmental hypoxia, hormones and cytokines30. 
The key regulator of hypoxia induced angiogenesis is 
transcription factor Hypoxia-induced-Factor (HIF-1)31. It 
was very early proposed that inhibiting angiogenesis can be 
effective antitumor strategy because tumor growth required 
for blood vessel formation32. VEGF mRNA is expressed in 
neoplastic cells where as endothelial cells express VEGFR1 
and VEGFR2 mRNA and proteins33. The increase in blood 
vessel formation helps tumor to gain necessary oxygen 
and nutrient. Tumor angiogenesis is a hall mark of cancer 
which supports tumor growth and metastasis34.
VEGFA binds to progenitor cells which express 
VEGFR1 and induce suppression of NF-κB activation and 
signal transduction pathway35. In Breast cancer, VEGF-A 
expression is associated with increase in microvessel 
density36. Clinical trials confirm that VEGF expression is 
an indicator for relapse –free survival32,37. It has also been 
found that VEGF is essential for initial subcutaneous growth 
of breast carcinoma cells38. Recent studies also suggest that 
upregulated VEGF-A is associated with poor prognosis in 
non-small cell lung carcinoma39. Low VEGF-D to VEGF-C 
ratio in tumors correlates with both lymphnode metastasis 
and lymphatic invasion by cancer cell40. In colorectal 
cancer, VEGFA expression is stepwise upregulated for 
MVD and VEGF-C correlates with extent of lymph node 
metastasis36,40. In prostate cancer VEGFA expression is 
reported to play a role in advancing focal carcinoma, 
invasion and metastasis32.
Because of above vital roles VEGF plays in cancer via 
upregulating angiogenesis there is lot of focus on targeting 
VEGF for advanced anti-cancer strategies. Antibody based 
strategies to target VEGF are extensively being studied. 
Currently more than 20 monoclonal antibodies are 
approved by FDA for therapeutic use41. Example:
1. Monoclonal antibodies
 a. Rituximab against CD20 for non-hodgkin   
 lymphoma42
b. Trastuzumab for breast cancer43
c. Cetuximab for metastatic colorectal cancer and 
head and neck cancer44
2. Antibodies with fusion protein 
a. Bevacizumab for metastatic colorectal cancer and 
non-small cell lung cancer and metastatic breast 
cancer45.
2.3 Epidermal Growth Factor Family
Epidermal growth factor family (EGF) is a complex 
network that modulates growth of cells. EGF is released by 
cells and then either by autocrine signaling i.e. stimulates 
its own growth or paracrine signaling i.e. stimulate growth 
of neighboring cells46. Ligands known to bind to EGFR are 
Epidermal growth factor (EGF), Transforming Growth 
Factor-α (TGF-α), amphiregulin, heparin-binding EGF-
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like growth factor, Betacellulin and Epiregulin47. EGFR are 
Receptor tyrosine kinases and they belong to ErbB family 
which consists of Erb-1 (EGFR), ErbB-2 (HER2 or Neu), 
ErbB-3, Erb448
EGF has been known to be mitogenic for mesenchymal 
and epithelial cells49. EGF stimulus to normal cells causes 
them to transform into neoplastic cells by increasing the 
level of phosphotyrosine in proteins50 and increase in 
sugar and aminoacid metabolism. Expression of c-fos and 
c-myc is upregulated by EGF51. EGF has also been found 
to play a vital role in viral carcinogenesis as it enhances 
viral transformation of cells52. Chemical carcinogenesis of 
methylcholantherene in skin is enhanced by EGF53. EGF 
phosphorylates tyrosine residues of src, erb, abl, yes, fgr, 
ros, fes (fps) and fms54.
Human breast cancer cell line like MCF-7 was found 
to synthesize and secrete EGF-like immunoreactive factor 
in culture55. Prostate cancer cell lines DU-145 were also 
found to secrete EGF-like polypeptides into serum-free 
culture medium56. Overexpression of TGF-α and EGFR by 
carcinomas are correlated to chemotherapeutic resistance, 
metastasis, and poor prognosis57. EGF-like peptides and 
erbB receptor induce transformation of cells in transgenic 
mice models. Evidences support that expression of rodent 
p-185c-neu and EGFR in Nh-373 cells is necessary for 
neoplastic transformation58. EGF overexpression has been 
found in metastatic breast cancer and aggressive form of 
uterine cancer59. Erb3 is associated in human mammary 
cancers. ErbB1/EGFR cases have accelerated intraepithelial 
proliferation48,60.
Therapeutic interventions against EGF 
includessuramine which inhibits the binding of EGF to its recetor61 and gefinitib which targets ErbB1 tyrosine kinase 
activity which causes inhibition of autophosphorylation62. 
Cetuximab, a monoclonal antibody which prevents ErbB1 
signaling by binding to the ligand binding domain is now 
being clinically used63.
2.4 Fibroblast Growth Factor Family
In humans, FGF family has 23 polypeptide encoding 
genes. Fibroblast growth factor family includes FGF1 i.e. 
acidic FGF, FGF-2 i.e. basic FGF and FGF-6 and FGF8. FGF 
receptors comprises of FGFR1-4 which are involved in both 
autocrine and paracrine signaling64. FGF are mitogenic 
for epithelial and mesenchymal cells. FGFs were first 
angiogenic factors to be indentified65 and hence posses 
high angiogenic activity66 in addition to enhancing motility 
and invasiveness of cells67.
FGF signaling is a must for sustained self-renewal and 
pluripotency of human embryonic stem cells (HESCs)68. 
During haematopoiesis, FGF stimulates growth of progenitor 
cells69. FGF-2 stimulus leads to neoplastic transformation 
of cells70. Elevated levels of FGF2 in micro-environment 
of metastatic prostate cancer help cells to evade the anti-
proliferative effect of chemotherapy71. Myeloma-associated 
oncogene FGFR3 is upregulated in cancer cells from 
patients with Chronic Myeloid leukemia (CML)67,72.
Transgenic mice with both epithelial FGF3 
overexpression and FGFR1 activation lead to epithelial 
proliferation and invasion of lesions73. FGFR2IIIb knockout 
mice fail to develop branching morphogenesis in breast 
which suggests that FGFR2 expression predisposes to breast 
cancer74. Single Nucleotide Polymorphisms occurring in 
FGFR2 and FGFR4 have been linked to their critical role in 
pathogenesis of breast cancer75. FGFR2 amplification occurs 
both in breast cancer and gastric cancer and is associated 
with poor prognosis76. Evidences indicating FGFR activating 
mutations specifically in FGFR2 are found in endometrium 
cancer77 and in FGFR3 are present in bladder cancer78.
FGF2 is present at increased levels in prostate cancer. 
FGF1 is found to be upregulated in 80% of prostate 
cancer which can be confirmed from IHC79. FGF1 has 
also been found to increase in prostatic intra-epithelial 
neoplasia (PIN)80. Transgenic mice with activated FGFR1 
kinase develop PIN81. FGFR4 plays a significant role in 
prostate cancer initiation as confirmed by the presence of 
homozygozicity for FGFR arg388 is associated occurrence 
of prostate cancer82.
A lot of efforts are being put to FGF/FGFR inhibitors. 
Data from phase I/II clinical trial proved that FGFR 
inhibitors exhibit antitumor activity. For example:
1.  Nonselective FGFRTKIs-Donovitinib83 inhibits FGFR, 
PDGFR and VEGFR.
Nintedanib84 potentially blocks VEGFR, PDGFR, FGFR. 
And   also targets SRC, LYN,LLK.Poratinib, an oralmultikinase 
inhibitors inhibits BCR-ABC85.
2.  Selective anti-FGF-TKIs- AZD454786 pan FGFR selective 
causes desregulation of FGFR expression and hence 
shows anticancer response.BGJ398 selectively inhibits 
FGFR1-3 and is in phase I clinical trial87.
2.5	 Transforming	 Growth	 Factor-β	 Family
Transforming growth family –β is a secreted 
cytokine that critically influences proliferation and 
cellular differentiation. It plays an important role in 
immunity, cancer, bronchial asthma, lung fibrosis, heart 
diseases, diabetes etc88. Ligands of TGF-β family are bone 
morphogeneic proteins (BMPs), growth and differentiation 
factors (GDFs), anti-mullerian hormone (AMH, activin, 
Nodal and TGF-β, TGF-β includes- TGF-β1, TGF-β2, TGF-
β389. 
There are 8 types of SMAD proteins divided in 3 
classes90:
i.  Receptor regulated SMAD (R-Smad) –Smad 1,2,3,5 
and 8.
ii.  Co-mediator SMAD (Co- Smad) – smad 4
iii.  Inhibitory SMAD (I-smad) – smad 6,7.
TGF-β signaling negatively regulates growth and 
inhibition of this pathway contributes to tumorigenesis91. As 
TGF-β negatively regulates growth, inactivating mutations 
in TGFBR1, TGFBR2, SMAD2, SMAD4 are commonly 
found in human cancers. In addition to this there is also 
loss of expression of TGF-β and Smad in many cancers. 
Disruption of TGF-β activated Smad pathway is sufficient 
to change gene expression which accelerates tumor 
formation. SMAD proteins play important role in TGF-β 
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associated growth inhibition and apoptosis. Rho proteins 
and PI3K regulate cell shape, loss of adherens junction and 
motility92. Colon, gastric, billary, pulmonary and ovarian 
cancer witness biallelic inactivation of TGFBRIII, which 
leads to inhibition of kinase domain of the receptor93. Some 
proteins called as ‘ligand traps’ trapTGF-β family members 
so that their membrane access can be stopped. Example 
Folistatin trap BMPs and it is found to be overexpressed 
in hepatocarcinoma94 and breast cancer bone metastasis95. 
Germin-1 dysregulated expression is associated with skin 
and other cancer96.
Intragenic mutation in SMAD4 occurs in colorectal 
cancer97. Gastric cancer and T-cell lymphoblastic leukemia 
has been characterised by Loss of Smad3 expression93. 
Smad2 and Smad3 protein expression  is decreased in 
epithelial human cancers and rat prostatic carcinomas98 
and expression of Smad6 and Smad7 is increased99.
2.6 Insulin-like Growth Factor Family 
Insulin-like growth factors are associated with 
regulation of metabolism, growth and survival101. The 
signaling pathway utilized by IGF includes phosphoinositide-
3-kinase (PI3K) and Akt or Ras and MAPK, which mediates 
response to many stimuli102. IGF family is constituted of 
two polypeptide ligands (IGF-1 and IGF-2), two membrane 
bound receptors (IGF-IR, IGF-IIR) and six binding proteins 
(IGFBP-1,2,3,4,5,6)103. IGF-I increases cellular uptake of 
amino acids and glucose and stimulates glycogen and 
protein synthesishence exerting a anabolic effect on 
protein and carbohydrate metabolism104. IGF-I plays role 
in cell proliferation, differentiation and apoptosis. IGF-1 
stimulates expression of Bcl proteins and hence blocks the 
initiation of apoptosis105. IGF-II has mitogenic and anti-
apoptotic action and also regulates cell proliferation and 
differentiation106. 
IGFBPs have both IGF-dependent and IGF-independent 
functions. When IGFBPs bind to IGFs, they help in 
transporting IGFs, protecting IGFs from proteosomal 
degradation, and regulate the interaction between IGFs and 
IGf-IR107.
IGF-I and IGF-II are associated with variety of cancer 
like sarcoma, leukemia, prostate, breast, lung, colon, 
stomach, esophageal, liver, pancreas, kidney, thyroid, brain, 
ovary and uterus108. Cancer cells having high metastatic 
potential have higher expression of IGF-II and IGF-IR. IGF-
IR elimination from cell inhibits the signal transduction, 
abolishing the mitogenic activation of IGFs in cancer cells109. 
IGF-IIR antagonizes effect of TGF-II and loss of function of 
IGF-IIR is associated in cancer and cancer cells which lack 
IGF-II degrading ability have good growth profile110. The 
action of IGFs is regulated by IGFBPs in cancer111. 
Oh112, et al.  found that IGFBP-3 inhibits breast cancer 
cell growth and induces apoptosis in both breast cancer 
and prostate cancer113. This happens because of presence of 
IGFBPs proteases. It was emphasized that increased levels 
of IGF-I is associated with increased breast cancer risk114. 
Increased levels of IGF-I and II are reported in colorectal 
cancer and hepatocarcinoma115,116. In pancreatic cancer 
pathway, mTOR is the point intersection, which allows 
IGF-IR/GPCR interaction to potentiate cell growth and 
proliferation117. IGFs can cause direct HIF-1α expression 
through MAPK/PI3K pathway and IGF-IR synthesis occurs 
during hypoxia leading to neoangiogenesis118.
IGF pathway is an interesting target for cancer 
therapeutics. The mainstay of IGF target therapy is:
1. Small molecule inhibitors which inhibits tyrosine 
kinase domain of IGF-IR. (eg. Tyrophosphins, 
Picropodopyllins, INSM-18, BNS-754807119.
2. Monoclonal antibodies (mAb) directed at IGF-IR. (eg. 
Ganitumab, AVE-1642, MK-0646, cixutumunab)120.
OS7-906 is a small molecule TKIs that attaches to ATP 
binding site of tyrosine kinase receptor and causes dual 
inhibition of IR and IGF-IR121. Picropodophyllins inhibit 
IGF-IR. Exelixis are multitarget TKIs inhibit IGF-IR and Bcr-
abl kinase122. Epigallocatechins is a catechinpolyphenolic 
component of green tea. It phosphorylates and activates TK 
and activates TK and inhibits IGF-IR by autophosphorylation 
of IGF-IR tyrosine kinase which causes cell cycle arrest123.
Ganitumab is monoclonal antibody with IgG1 back bone 
and inhibits ligand binding of IGF-1 and-2 which inhibts 
IGF-IR phosphorylation124. AVE-1642 bind to IGF-IR and 
inhibits binding of IGFs. Cixutumunab is a fully humanised 
antibody blocking IGF-Rs and is in clinical trial phase II for 
breast cancer125.
2.7 Hepatocyte Growth Factor Family
Hepatocyte growth factor (HGF) is also known 
as Serum factor (SF, HGF mediates its action through 
binding to a specific receptor site c-Met126. HGF binds 
to extracellular α-chain of c-Met receptor leading to 
tyrosine phosphorylation of terminal kinase domain and 
progression of downstream pathways127. HGF is expressed 
mainly by mesenchymal cells. Activation of HGF includes 
Hepatocyte growth factor Activator (HGFA)128. Matriptase, 
matrix degrading serum protease converts pro-HGF to 
biologically active HGF (also Heparin, Factor XIII, tissue 
plasminogen activator (t-PA) and Urokinase Plasminogen 
activator (u-PA))129.
HGF is a mitogenic regulating cell growth and death130. HGF functions includes inhibition of apoptosis131, 
angiogenesis132, morphogenesis133 and regulator of organ 
development134.
Met is mainly expressed in epithelial cells whereas 
HGF is predominantly secreted by mesenchymal cells. 
This represents a cross-talk between epithelial cells and 
stromal cells135,136. The autocrine activation of Met occurs 
in osteosarcoma and glioblastomas. In breast cancer, it 
is activated by paracrine signaling137. Many carcinomas 
overexpress met as it is required for tumor growth and 
survival138. In hepatocytes, Met binds to Fas and inhibits Fas-
induced apoptosis. Mutations in Met have been evident in 
juxtamembrane in gastric and lung cancer139,140. Interaction 
between c-Met and RTKs is linked to development 
of resistance to cancer therapies141. C- Met interacts 
directly with epidermal growth factor (EGFR), allowing 
activation of c-Met after stimulation of cells with EGFR 
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ligands EGF or TGF-α142. Mutation in c-Met kinase domain 
were reported in human renal papillary carcinomas143. 
Genetically transmitted cancers might be due to presence of 
heterozygous mutations in c-CBL binding site144. Hypoxia, 
a usual oxygen deficient state in tumors activate c-Met 
transcription via HIF1α stabalisation145.
HGF has emerged as potentially good therapeutic 
target against cancer and following anti-cancer strategies 
have been devised:
(a) Against HGF: neutralizing antibodies, anti-sense 
oligonucleotides, ribozyme siRNA and HGF 
regulators146.
(b) Against c-Met: HGF antagonist, antibodies, small 
molecule inhibitors, antisense oligonucleotides, 
ribozymes, siRNA as non-specific inhibitors147.
(c) Against c-Met signaling events148.
(d) HGF activation inhibitors149.
(e) SRC inhibitors have also shown good primary results 
in treatment of cancer cells.
(f) HIF can also be good target as its stabilization leads to 
transcription of c-Met150. 
2.8 neurotrophin Family
It was found in 1990 that some secreted proteins 
were important to normal growth of neurons and dendritic 
cells. Later they were named as neurotrophins151. The first 
neurotrophin discovered was NGF (Nerve growth factor)152. 
And next was brain derived neurotrophic factor (BDNF, 
In mammals two more neurotrophins were discovered, 
neurotrophin 3 and neurotrophin 4 and 5.
Receptors for Neurotrophin are transmembrane 
receptor of two different classes i.e. Trks and neurotrophin 
receptor P75. The cell survival is mediated by Trk receptor 
whereas P75 induces cell death. Trk i.e. (tropomyosine 
receptor kinases ) are receptor tyrosin kinases and they 
are further categories into 3 types receptor types, TrkA153 
TrkB and TrkC. The preferred ligand for TrkA is NGF, where 
as for TrkB preffered ligand is BDNF and NT4/5 and TrkC 
binds preferentially to NTB154. P75 is a bundle of six short 
α-helixes spanning of 90 amino acids forming a fold but do 
not posses any intrinsic catalytic activity155.
Spingomyelin is hydrolysis to ceramide by P75156 
and after  ligand  binding causes dopamine release157. 
P75 interacts with caveolin following TNF-α and NFKβ 
activation158. NFG was discovered from sarcoma while 
human colon cancer biopsy revealed TrkA and P75 was 
isolated from human melanoma cell lines159. In breast 
cancer there is increase in NGF expression leading to 
phosphorylation mitogenesis, invasion, metastasis and 
angiogenesis via activation of all the three pathways i.e 
MAPK, PI3K/AKT and PLCγ160. In melanomas, NGF-mediated 
paracrine signaling promotes proliferation and invasion161. 
In prostate cancer there is loss of P75 protein in basal 
epithelium cells due to mRNA instability. Loss of function 
of P75 leads to cell survival, proliferation and metastasis162. 
In pancreatic cancer NGF expression is increased which 
enhances proliferation, invasion and tumorigenicity163.
In neuroblastoma TrKAIII isoforms potentiates 
survival via activation of PI3K-AKT pathway164. Whereas in 
glioblastoma NGF induces causes cell death by autophagy165 
and in medulloblastoma TrkA expression has good 
prognosis166. TrkA signaling can be inhibited by tyrosine 
kinase inhibitors such as indocarbazole167. Tamoxifen 
inhibits NGF mediated TrkA phosphorylation independent 
of its action on estrogen receptor168.
In phase I clinical trial neurotrophin receptor-linked 
tyrosine kinase receptor inhibitor, CEP-701 was found to 
be orally safe and has entered phaseII clinical trial169. The 
selective Trk inhibitorAZ613 was found active against 
neurotrophin factor- mediated proliferation and signaling 
of neuroblastoma cells170. The Trk tyrosine kinase inhibitor 
CEP-701 exhibited anti-tumor efficacy in xenograft models 
of human pancreatic ductal adenocarcinoma171. It has 
found that Lestaurtinib enhances the anticancer efficacy of 
chemotherapy in murine xenograft model of neuroblastoma 
via inhibition of TrkB activation and has promoted the 
clinical trial of Lestaurtinib172.
2.9 the Ephrin family
Ephrin expression play regulatory role in development 
and tissue homeostasis, along with  the formation of 
tissue boundries, assembly formation of neuronal mesh 
work, remodeling of blood vessels and organ size173. 
Eph receptors are largest family of receptor tyrosine 
kinase. They bind GPI-linked and transmembrane ephrin 
ligands, generating bidirectional signaling at site of cell-
cell contacts. Eph receptors are divided into two groups 
EphA and EphB, depending on two types of ligands that 
bind. EphA are further divided into 10 sub- groups EphA 
(EphA1-10) and EphB kinase (EphB1-6,Similarly there 
are two types of ephrin ligands: EphrinsA (A1-A6) and 
EphrinsB (B1-B3,EphrinA ligands are tethered to the cell 
membrane through glycosyl phosphotidyl-inositol (GP1) 
anchor. Whereas EphrinB ligands are transmembrane 
proteins possessing a cytoplasmic region and a PDZ-
binding motif174.
Expression of Ephs and Ephrins is frequently altered in 
human cancers. Eph receptors promote both tumorigenesis 
and tumor suppression175. EphA2 overexpression has 
been found to cause oncogenic mutations and promotes 
metastasis in murine breast cancer models176. EphB2 
provides survival advantage to breast cancer by attenuating 
the inherent cell death pathways and upregulated anti-
apoptotic proteins. EphB4 knockdown inhibit breast 
cancer cell viability, migration and invasion177. EphA1 is 
elevated in colorectal cancer cases. It is mostly detected 
in stage II178. Signaling EphA2 and EphrinA1 were more 
common in early stages of cancer. High expression of EphA3 
is associated with  lowersurvival rate179. It has been found 
that EphA2 is overexpressed in human prostate cancer 
and it is linked with metastasis180. EphA2 overexpression 
in associated with invasiveness in glioblastoma and 
is now important in targeted therapeutics against 
glioblastomas181. That overexpression of EphA4 enhances 
cell migration and proliferation through promoting the 
FGF signaling pathway182. EphB2 expression is higher in 
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invasive glioblastomas183. Metastatic melanoma cells are 
characterised by EphA2 expression184. EphrinA1,serves as 
growth factor, angiogenic signal and chemoattractant for 
melanoma cells but also angiogenic and chemoattractant 
for epithelial cells185. EphA2 promots angiogenesis186.
Therapeutic targets against ephrins and Ephs are 
classified as :
(i) Inhibition of receptor-ligand interactions187: 
 Eg a) EphA2-Fc, EphB3-Fc are used in breast cancer 
and pancreatic cancer that targets ephrinA.
  b) 2,5-dimethyl pyrrolyl benzoic acid derivatives target 
EphA4 to inhibit angiogenesis.
(ii) Activation of Eph forward signaling188: 
Eg   EA2, B233 antibody against EphA2 in breast 
cancer.
(iii) Kinase inhibitors: E.g. Dasatinib against EphA2 in 
prostate cancer.
(iv) Inhibition of Eph expression: E.g. EphA2 siRNA against 
pancreatic cancer and ovarian cancer189.
2.10 angiopoietins
Various growth factors are linked to physiological as 
well as pathological angiogenesis190. Angiopoietin family 
of growth factor is composed of four members that bind 
to same TIE-2 tyrosine kinase receptor leading to different 
consequences. Angiopoietins was discovered by Davis et al., 
in 1996191. On the basis of structure Angiopoietins (ANG) 
are classified as192:
1. ANG-1
2. ANG-2
3. ANG-3
4. ANG-4.
ANG-1 function is to stabilise and mature the blood 
vessels193. Whereas ANG-2 is produced by endothelial cells 
at the site of vascular remodeling and destabilizes the 
vessel by lossening the endothelial cell junctions. ANG-2 
acts as antagonist of ANG-1 because they compete with 
each other for TIE-2 receptor binding site194. ANG-3 acts 
in a similar way as ANG-1 promoting phosphorylation of 
TIE-2 receptortyrosine residues. ANG-4 effects are similar 
to ANG-2 acts as a antagonist of ANG-1192. Upregulated 
ANG-2 is correlated to metastasis in breast cancer and 
lung cancer195. Apart from cancer, ANG-2 upregulation is 
frequently found in diseases such as macula degeneration, 
rheumatoid arthritis196, osteoarthritis197, and psoriasis198. 
Major therapeutics targeting ANG-2 in clinical trial are:
(i) AMG-386: which is Fc-fusion protein blocks interaction 
between ANG-1 and ANG-2 and TIE-2 receptor. It 
is proposed to be effective in multiple cancers like 
ovarian, breast, fallopian tube cancer199.
(ii) CVX-060: it selectively blocks ANG-2 and TIE-2 
interaction and has a very long half-life. It is in trials 
in combination with sunitinib, sorafenib, bevacizumab 
and irinotecan200.
(iii) CEP-11981: it is found to inhibitor of both VEGF and 
TIE-2 receptor tyrosine kinase201.
(iv) MED13617: it is human anti-ANG-2 mAb. It has been 
shown to decreases angiogenesis and retard tumor 
growth in mouse models in combination with mAb 
bevacizumab202. 
3. PErsPEctIVE 
Growth factors are necessary for normal growth of non-
transformed cells. Theses cells perform their committed 
physiological functions via availability of growth factors. 
But the signaling in normal cells is limited as the growth 
factors are depleted at the site by various degrading 
pathways. But as discussed by Hanahan and Weinberg, the 
first hallmark of cancer is self-sufficiency of growth signals, 
which has two advantages. Firstly, because of continued 
availability of growth factors the check points of cell 
cycle can be overcome. Secondly, the growth suppressor 
signaling is bypassed. Hence abrupt signaling can induce 
oncogenic transformations. An enhanced understanding 
of these pathways can help targeting these neoplastic 
transformation at an early stage.
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